Altimmune (ALT)
NASDAQ:ALT
Want to see ALT full AI Analyst Report?
ALT Stock Chart & Stats
$3.50
$0.16(2.19%)
At close: 4:00 PM EST
$3.50
$0.16(2.19%)
Day’s Range― - ―
52-Week Range$2.56 - $7.73
Previous CloseN/A
Volume1.55M
Average Volume (3M)4.65M
Market Cap
$563.98M
Enterprise Value$207.43M
Total Cash (Recent Filing)$331.54M
Total Debt (Recent Filing)$35.85M
Price to Earnings (P/E)―
Beta1.59
Next Earnings
Aug 06, 2026EPS Estimate
-0.15Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.93
Shares Outstanding194,474,150
10 Day Avg. Volume2,680,334
30 Day Avg. Volume4,654,014
Financial Highlights & Ratios
PEG Ratio0.14
Price to Book (P/B)1.41
Price to Sales (P/S)7757.46
P/FCF Ratio-4.71
Enterprise Value/Market Cap0.37
Enterprise Value/Revenue5.76K
Enterprise Value/Gross Profit-13.88
Enterprise Value/Ebitda-2.22
Forecast
1Y Price Target
$13.30Price Target Upside280.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
EPS Forecast (FY)-0.69
Revenue Forecast (FY)$5.13K
Bulls Say, Bears Say
Bulls Say
Balance-sheet StrengthA debt-free balance sheet with meaningful equity provides durable financial flexibility to fund late-stage development and absorb trial timing variability. This reduces short-term refinancing risk and supports strategic choices (CROs, supply chain, comparability studies) over the next 2–6 months.
Secured Financing & RunwayA successful oversubscribed equity raise that materially increased cash to pro forma ~$535M meaningfully extends runway through planned Phase III 52-week readout. This durable capital base lowers near-term dilution risk and enables Phase III start-up and global operational commitments.
Regulatory & Phase III ReadinessAlignment with FDA/EMA and a finalized global Phase III protocol (CRO engaged, H2 2026 start planned) materially reduces regulatory uncertainty and execution ambiguity. This regulatory recognition shortens decision pathways and supports predictable development timelines over coming quarters.
Bears Say
Ongoing Cash BurnSustained negative operating and free cash flows indicate continued reliance on financing for operations. Even with recent proceeds, persistent burn will deplete resources over time absent revenue or cost reductions, keeping financing and dilution risk relevant across the next several quarters.
Large Losses, Almost No RevenueVery large, recurring operating losses and minimal revenue reflect an absence of commercial cash generation. Profitability depends entirely on clinical and regulatory success; failure or delays in trials would pressure equity value and make long-term self-funding unlikely.
Competitive & Execution RiskA crowded GLP-1 and multi-agonist market and recent positive comparator data increase the need for clear differentiation on tolerability and liver targeting. Combined with complex biopsy/digital-pathology execution, this elevates commercialization and regulatory risks over the medium term.
Altimmune News
ALT FAQ
What was Altimmune’s price range in the past 12 months?
Altimmune lowest stock price was $2.56 and its highest was $7.73 in the past 12 months.
What is Altimmune’s market cap?
Altimmune’s market cap is $563.98M.
When is Altimmune’s upcoming earnings report date?
Altimmune’s upcoming earnings report date is Aug 06, 2026 which is in 63 days.
How were Altimmune’s earnings last quarter?
Altimmune released its earnings results on May 13, 2026. The company reported -$0.18 earnings per share for the quarter, beating the consensus estimate of -$0.242 by $0.062.
Is Altimmune overvalued?
According to Wall Street analysts Altimmune’s price is currently Undervalued.
Does Altimmune pay dividends?
Altimmune pays a Monthly dividend of $873 which represents an annual dividend yield of N/A. See more information on Altimmune dividends here
What is Altimmune’s EPS estimate?
Altimmune’s EPS estimate is -0.15.
How many shares outstanding does Altimmune have?
Altimmune has 194,474,150 shares outstanding.
What happened to Altimmune’s price movement after its last earnings report?
Altimmune reported an EPS of -$0.18 in its last earnings report, beating expectations of -$0.242. Following the earnings report the stock price went down -1.948%.
Which hedge fund is a major shareholder of Altimmune?
Currently, no hedge funds are holding shares in ALT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Altimmune Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$13.30 (280.00% Upside)
$13.30 (280.00% Upside)
Blogger Sentiment
Bullish
ALT Sentiment 70%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth $198.1K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▲ 1.3%
Last 30 Days ▼ 0.4%
Last 30 Days ▼ 0.4%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-45.28%
12-Months-Change
Fundamentals
Return on Equity
-42.57%
Trailing 12-Months
Asset Growth
113.42%
Trailing 12-Months
Company Description
Altimmune
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.
ALT Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed significant progress: strong financing ($225M offering; $535M pro forma cash), regulatory recognition (Breakthrough Therapy), alignment with FDA/EMA on the PERFORMA Phase III protocol, robust Phase II efficacy/tolerability signals, and near-term readouts (AUD topline; RESTORE enrollment). Challenges were mostly operational and expected for a late-stage biotech: higher G&A and R&D as programs advance, a wider net loss in the quarter, ongoing validation/integration of digital pathology tools, and a competitive landscape necessitating clear differentiation. Overall, the positives — especially the cash runway and Phase III readiness — materially outweigh the manageable execution and competitive risks.View all ALT earnings summariesALT Stock 12 Month Forecast
Average Price Target
$13.30
▲(280.00% Upside)
Technical Analysis
Tvardi Therapeutics
―
Diamedica Therapeutics
―
Alpha Tau Medical Ltd
―
enGene Holdings
―
Lexeo Therapeutics, Inc.
―
Ownership Overview
0.45% Insiders
8.62% Mutual Funds
3.26% Other Institutional Investors
76.05% Public Companies and Individual Investors